{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:49:20Z","timestamp":1788306560826,"version":"build-2803163510"},"reference-count":42,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,10]],"date-time":"2020-01-10T00:00:00Z","timestamp":1578614400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004442","name":"Narodowym Centrum Nauki","doi-asserted-by":"publisher","award":["2012\/07\/N\/NZ7\/04315"],"award-info":[{"award-number":["2012\/07\/N\/NZ7\/04315"]}],"id":[{"id":"10.13039\/501100004442","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004569","name":"Ministerstwo Edukacji i Nauki","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004569","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009647","name":"Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009647","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007037","name":"Ministeriet Sundhed Forebyggelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007037","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.vaccine.2020.01.021","type":"journal-article","created":{"date-parts":[[2020,1,21]],"date-time":"2020-01-21T18:12:21Z","timestamp":1579630341000},"page":"1943-1952","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Genetic variability of Polish serogroup B meningococci (2010\u20132016) including the 4CMenB vaccine component genes"],"prefix":"10.1016","volume":"38","author":[{"given":"Izabela","family":"Wa\u015bko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Go\u0142\u0119biewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlena","family":"Kiedrowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrycja","family":"Ronkiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izabela","family":"Wr\u00f3bel-Pawelczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicja","family":"Kuch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Skoczy\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2020.01.021_b0005","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/j.vaccine.2017.03.007","article-title":"The epidemiology of invasive meningococcal disease in EU\/EEA countries, 2004\u20132014","volume":"35","author":"Whittaker","year":"2017","journal-title":"Vaccine"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2020.01.021_b0010","doi-asserted-by":"crossref","first-page":"B51","DOI":"10.1016\/j.vaccine.2009.04.063","article-title":"Global epidemiology of meningococcal disease","volume":"27","author":"Harrison","year":"2009","journal-title":"Vaccine"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2020.01.021_b0015","doi-asserted-by":"crossref","first-page":"B71","DOI":"10.1016\/j.vaccine.2009.04.070","article-title":"Biology and pathogenesis of the evolutionarily successful, obligate human bacterium Neisseria meningitidis","volume":"27","author":"Stephens","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.01.021_b0020","doi-asserted-by":"crossref","first-page":"313","DOI":"10.5604\/17331331.1185912","article-title":"Significance of Meningococcal Hyperinvasive Clonal complexes and their influence on vaccines development","volume":"64","author":"Wa\u015bko","year":"2015","journal-title":"Pol J Microbiol"},{"key":"10.1016\/j.vaccine.2020.01.021_b0025","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.micpath.2013.02.003","article-title":"Neisseria meningitidis serogroup B vaccine development","volume":"57","author":"Caesar","year":"2013","journal-title":"Microb Pathog"},{"issue":"Suppl 2","key":"10.1016\/j.vaccine.2020.01.021_b0030","doi-asserted-by":"crossref","first-page":"B87","DOI":"10.1016\/j.vaccine.2012.01.033","article-title":"The new multicomponent vaccine against meningococcal serogroup B, 4CMenB; immunological, functional and structural characterization of the antigens","volume":"30","author":"Serruto","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.01.021_b0035","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1586\/erv.11.103","article-title":"Neisseria meningitidis B vaccines","volume":"10","author":"Panatto","year":"2011","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2020.01.021_b0040","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/1471-2334-10-175","article-title":"The elusive meningococcal meningitis serogroup: a systematic review of serogroup B epidemiology","volume":"10","author":"Racloz","year":"2010","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2020.01.021_b0045","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.jinf.2015.09.035","article-title":"The introduction of the meningococcal B (MenB) vaccine (Bexsero(R)) into the national infant immunisation programme\u2013new challenges for public health","volume":"71","author":"Ladhani","year":"2015","journal-title":"J Infect"},{"key":"10.1016\/j.vaccine.2020.01.021_b0050","article-title":"Centre for Disease Prevention and Control. Expert opinion on the introduction of the meningococcal B (4CMenB) vaccine in the EU\/EEA","author":"European","year":"2017","journal-title":"Stockholm"},{"key":"10.1016\/j.vaccine.2020.01.021_b0055","first-page":"20","article-title":"A prolonged outbreak of invasive meningococcal disease in an extended Irish Traveller family across three Health Service Executive (HSE) areas in Ireland, 2010 to 2013","author":"O'Connor","year":"2015","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2020.01.021_b0060","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.vaccine.2015.11.057","article-title":"Clinical experience with the meningococcal B vaccine, Bexsero((R)): prospects for reducing the burden of meningococcal serogroup B disease","volume":"34","author":"Watson","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.01.021_b0065","first-page":"23","article-title":"Community outbreak of serogroup B invasive meningococcal disease in Beaujolais, France, February to June 2016; from alert to targeted vaccination","author":"Thabuis","year":"2018","journal-title":"Euro Surveill"},{"key":"10.1016\/j.vaccine.2020.01.021_b0070","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1016\/j.vaccine.2015.04.015","article-title":"MATS: Global coverage estimates for 4CMenB, a novel multicomponent meningococcal B vaccine","volume":"33","author":"Medini","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.01.021_b0075","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1016\/j.vaccine.2016.08.015","article-title":"Distribution of Bexsero(R) Antigen Sequence Types (BASTs) in invasive meningococcal disease isolates: implications for immunisation","volume":"34","author":"Brehony","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.01.021_b0080","doi-asserted-by":"crossref","first-page":"673","DOI":"10.3201\/eid2404.171480","article-title":"Genomic surveillance of 4CMenB vaccine antigenic variants among disease-causing Neisseria meningitidis isolates, United Kingdom, 2010\u20132016","volume":"24","author":"Rodrigues","year":"2018","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2020.01.021_b0085","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0158315","article-title":"Temporal changes in BEXSERO(R) antigen sequence type associated with genetic lineages of Neisseria meningitidis over a 15-year period in Western Australia","volume":"11","author":"Mowlaboccus","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2020.01.021_b0090","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.vaccine.2018.12.061","article-title":"Genetic Meningococcal Antigen Typing System (gMATS): a genotyping tool that predicts 4CMenB strain coverage worldwide","volume":"37","author":"Muzzi","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.01.021_b0095","unstructured":"ECDC. Annual Epidemiological Reports on meningococcal disease. https:\/\/ecdc.europa.eu\/en\/meningococcal-disease\/surveillance-and-disease-data\/aer. Accessed August 2019."},{"key":"10.1016\/j.vaccine.2020.01.021_b0100","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s40121-019-0254-1","article-title":"Epidemiologic trends, global shifts in Meningococcal vaccination guidelines, and data supporting the use of MenACWY-TT vaccine: a review","volume":"8","author":"Presa","year":"2019","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.vaccine.2020.01.021_b0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0071943","article-title":"A decade of invasive meningococcal disease surveillance in Poland","volume":"8","author":"Skoczynska","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2020.01.021_b0110","unstructured":"NRCBM. Invasive Meningococcal disease in Poland in 2018. koroun.edu.pl\/wp-content\/uploads\/2019\/05\/ICHM2018.pdf. Accessed August 2019."},{"key":"10.1016\/j.vaccine.2020.01.021_b0115","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1128\/CVI.00027-10","article-title":"Characterization of fHbp, nhba (gna2132), nadA, porA, and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008 and potential coverage of an investigational group B meningococcal vaccine","volume":"17","author":"Lucidarme","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2020.01.021_b0120","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1128\/CVI.00055-11","article-title":"Characterization of Neisseria meningitidis isolates that do not express the virulence factor and vaccine antigen factor H binding protein","volume":"18","author":"Lucidarme","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2020.01.021_b0125","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1128\/jcm.26.11.2465-2466.1988","article-title":"Numerical index of the discriminatory ability of typing systems: an application of Simpson's index of diversity","volume":"26","author":"Hunter","year":"1988","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2020.01.021_b0130","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.vaccine.2015.11.070","article-title":"High predicted strain coverage by the multicomponent meningococcal serogroup B vaccine (4CMenB) in Poland","volume":"34","author":"Wa\u015bko","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.01.021_b0135","unstructured":"NIPH-NIH. Reports on cases of infectious diseases and poisonings in Poland. http:\/\/wwwold.pzh.gov.pl\/oldpage\/epimeld\/index_a.html. Accessed August 2019."},{"key":"10.1016\/j.vaccine.2020.01.021_b0140","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0167762","article-title":"Serogroup and clonal characterization of Czech Invasive Neisseria meningitidis strains Isolated from 1971 to 2015","volume":"11","author":"Jandova","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2020.01.021_b0145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0150721","article-title":"Predicted strain coverage of a new meningococcal multicomponent vaccine (4CMenB) in Spain: analysis of the differences with other European countries","volume":"11","author":"Abad","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2020.01.021_b0150","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S1473-3099(17)30170-6","article-title":"Meningococcal serogroup B strain coverage of the multicomponent 4CMenB vaccine with corresponding regional distribution and clinical characteristics in England, Wales, and Northern Ireland, 2007\u201308 and 2014\u201315: a qualitative and quantitative assessment","volume":"17","author":"Parikh","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2020.01.021_b0155","doi-asserted-by":"crossref","DOI":"10.1128\/mSphere.00261-17","article-title":"Meningococcal antigen typing system (MATS)-based Neisseria meningitidis serogroup B coverage prediction for the MenB-4C vaccine in the United States","volume":"2","author":"Rajam","year":"2017","journal-title":"mSphere"},{"key":"10.1016\/j.vaccine.2020.01.021_b0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0176177","article-title":"Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Portugal","volume":"12","author":"Simoes","year":"2017","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2020.01.021_b0165","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1155\/2015\/393659","article-title":"Characterization of invasive Neisseria meningitidis from Atlantic Canada, 2009 to 2013: With special reference to the nonpolysaccharide vaccine targets (PorA, factor H binding protein, Neisseria heparin-binding antigen and Neisseria adhesin A)","volume":"26","author":"Tsang","year":"2015","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"10.1016\/j.vaccine.2020.01.021_b0170","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1473-3099(13)70006-9","article-title":"Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment","volume":"13","author":"Vogel","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2020.01.021_b0175","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1086\/600141","article-title":"Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis","volume":"200","author":"Murphy","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.01.021_b0180","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/6318254d-3f13-4cca-8bbe-08d0ff29aa64","article-title":"Molecular epidemiology of Neisseria meningitidis serogroup B in Brazil","volume":"7","author":"de Filippis","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2020.01.021_b0185","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1016\/j.vaccine.2017.03.057","article-title":"Prevalence of factor H Binding Protein sub-variants among Neisseria meningitidis in China","volume":"35","author":"Shi","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.01.021_b0190","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/1471-2180-14-111","article-title":"Diversity of Greek meningococcal serogroup B isolates and estimated coverage of the 4CMenB meningococcal vaccine","volume":"14","author":"Tzanakaki","year":"2014","journal-title":"BMC Microbiol"},{"key":"10.1016\/j.vaccine.2020.01.021_b0195","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s12866-015-0469-6","article-title":"Characterization of invasive Neisseria meningitidis strains from Quebec, Canada, during a period of increased serogroup B disease, 2009\u20132013: phenotyping and genotyping with special emphasis on the non-carbohydrate protein vaccine targets","volume":"15","author":"Law","year":"2015","journal-title":"BMC Microbiol"},{"key":"10.1016\/j.vaccine.2020.01.021_b0200","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1099\/jmm.0.079921-0","article-title":"Determination of serotyping antigens, clonal analysis and genetic characterization of the 4CMenB vaccine antigen genes in invasive Neisseria meningitidis from Western Canada, 2009 to 2013","volume":"63","author":"Law","year":"2014","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.vaccine.2020.01.021_b0205","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1084\/jem.20020407","article-title":"NadA, a novel vaccine candidate of Neisseria meningitidis","volume":"195","author":"Comanducci","year":"2002","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2020.01.021_b0210","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1016\/j.vaccine.2009.02.098","article-title":"Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus","volume":"27","author":"Bambini","year":"2009","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20300360?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20300360?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:40:17Z","timestamp":1759401617000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20300360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":42,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0264410X20300360"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.01.021","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genetic variability of Polish serogroup B meningococci (2010\u20132016) including the 4CMenB vaccine component genes","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.01.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}